Generic name: AFATINIB 20mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on Oct 18, 2019.
Patient Selection for Non-Resistant EGFR Mutation-Positive Metastatic NSCLC
Select patients for first-line treatment of metastatic NSCLC with GILOTRIF based on the presence of non-resistant EGFR mutations in tumor specimens [see Clinical Pharmacology (12.1), Clinical Studies (14.1)]. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended dosage of GILOTRIF is 40 mg orally once daily until disease progression or no longer tolerated by the patient.
Take GILOTRIF at least 1 hour before or 2 hours after a meal.
Do not take a missed dose within 12 hours of the next dose.
Dosage Modifications for Adverse Reactions
Withhold GILOTRIF for:
- Grade* 3 or higher adverse reactions
- Diarrhea of Grade 2 persisting for 2 or more consecutive days while taking anti-diarrheal medication [see Warnings and Precautions (5.1)]
- Cutaneous reactions of Grade 2 that are prolonged (lasting more than 7 days) or intolerable [see Warnings and Precautions (5.2)]
* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v 3.0
Resume treatment when the adverse reaction fully resolves, returns to baseline, or improves to Grade 1. Reinstitute GILOTRIF at a reduced dose, i.e., 10 mg per day less than the dose at which the adverse reaction occurred.
Permanently discontinue GILOTRIF for:
- Life-threatening bullous, blistering, or exfoliating skin lesions [see Warnings and Precautions (5.2)]
- Confirmed interstitial lung disease (ILD) [see Warnings and Precautions (5.3)]
- Severe drug-induced hepatic impairment [see Warnings and Precautions (5.4)]
- Gastrointestinal perforation [see Warnings and Precautions (5.5)]
- Persistent ulcerative keratitis [see Warnings and Precautions (5.6)]
- Symptomatic left ventricular dysfunction [see Adverse Reactions (6.1)]
- Severe or intolerable adverse reaction occurring at a dose of 20 mg per day
Dosage Modification for Pre-Existing Severe Renal Impairment
The recommended dosage of GILOTRIF in patients with pre-existing severe renal impairment (estimated glomerular filtration rate [eGFR*] 15 to 29 mL/min /1.73 m2) is 30 mg orally once daily [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
* Use the Modification of Diet in Renal Disease [MDRD] formula to estimate eGFR.
Dosage Modifications for Drug Interactions
Reduce GILOTRIF daily dose by 10 mg if not tolerated for patients who require therapy with a P-glycoprotein (P-gp) inhibitor. Resume the previous dose after discontinuation of the P-gp inhibitor as tolerated [see Drug Interactions (7), Clinical Pharmacology (12.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Gilotrif (afatinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Imprints, Shape & Color Data
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Drug class: multikinase inhibitors
- FDA Approval History